NASDAQ:RDEA - Ardea Biosciences Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Ardea Biosciences (NASDAQ:RDEA)

Ardea Biosciences logoArdea Biosciences, Inc. (Ardea) is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. The Company's product portfolio includes Lesinurad (RDEA594), RDEA3170 and BAY 86-9766 (RDEA119). Lesinurad (RDEA594) is an inhibitor of the URAT1 kidney transporter for the treatment of gout. RDEA3170 is a URAT1 kidney transporter inhibitors for the treatment of gout. BAY 86-9766 (RDEA119) is a MEK inhibitor for the treatment of cancer. On June 19, 2012, AstraZeneca PLC acquired the Company.

Receive RDEA News and Ratings via Email

Sign-up to receive the latest news and ratings for RDEA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:RDEA
CUSIPN/A
Phone+1-858-6526500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Ardea Biosciences (NASDAQ:RDEA) Frequently Asked Questions

What is Ardea Biosciences' stock symbol?

Ardea Biosciences trades on the NASDAQ under the ticker symbol "RDEA."

Has Ardea Biosciences been receiving favorable news coverage?

Headlines about RDEA stock have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardea Biosciences earned a daily sentiment score of 0.10 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 44.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Ardea Biosciences?

Shares of RDEA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Ardea Biosciences?

Ardea Biosciences' mailing address is 4939 Directors Pl, SAN DIEGO, CA 92121-3829, United States. The biotechnology company can be reached via phone at +1-858-6526500.


MarketBeat Community Rating for Ardea Biosciences (RDEA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  128
MarketBeat's community ratings are surveys of what our community members think about Ardea Biosciences and other stocks. Vote "Outperform" if you believe RDEA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDEA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ardea Biosciences (NASDAQ:RDEA) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/25/2016 forward)

Earnings

Ardea Biosciences (NASDAQ:RDEA) Earnings History and Estimates Chart

Earnings by Quarter for Ardea Biosciences (NASDAQ:RDEA)

Ardea Biosciences (NASDAQ RDEA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2012Q1 2012($0.97)($1.25)ViewN/AView Earnings Details
3/9/2012Q4 2011($0.87)($1.15)ViewN/AView Earnings Details
11/4/2011Q3 2011($0.67)($0.84)ViewN/AView Earnings Details
8/5/2011Q2 2011($0.52)($0.68)ViewN/AView Earnings Details
5/9/2011Q1 2011($0.50)($0.59)ViewN/AView Earnings Details
3/11/2011Q4 2010($0.56)($0.03)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.52)($0.79)ViewN/AView Earnings Details
8/6/2010Q2 2010($0.46)($0.57)ViewN/AView Earnings Details
5/7/2010Q1 2010($0.51)($0.54)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.28)($0.34)ViewN/AView Earnings Details
11/6/2009Q3 2009($0.47)($0.13)ViewN/AView Earnings Details
8/7/2009Q2 2009($0.60)($0.44)ViewN/AView Earnings Details
5/8/2009Q1 2009($0.74)($0.79)ViewN/AView Earnings Details
3/13/2009Q4 2008($0.95)($0.82)ViewN/AView Earnings Details
11/13/2008Q3 2008($1.08)($0.95)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.94)($1.10)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.74)($0.93)ViewN/AView Earnings Details
3/24/2008Q4 2007($0.84)($0.86)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ardea Biosciences (NASDAQ:RDEA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ardea Biosciences (NASDAQ RDEA) Insider Trading and Institutional Ownership History

Insider Trading History for Ardea Biosciences (NASDAQ:RDEA)

Ardea Biosciences (NASDAQ RDEA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Ardea Biosciences (NASDAQ RDEA) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Ardea Biosciences (NASDAQ:RDEA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ardea Biosciences (NASDAQ:RDEA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ardea Biosciences (NASDAQ RDEA) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.